"Biotechnology in Belgium - Market Research Report"
Biotechnology in Belgium - Market Research Report For more details on the content of report and ordering information please visit: http://www.aarkstore.com/reports/Biotechnology-in-Belgium-32122.html Introduction Biotechnology in Belgium industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Belgium biotechnology market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information. Highlights *AstraZeneca PLC *The biotechnology market consists of the development, manufacturing and marketing of products based on advanced biotechnology research. The market value reflects revenues of companies within this industry from product sales, licensing fees, royalties and research funding. Any currency conversions used in the creation of this report have been calculated using constant 2011 annual average exchange rates. *The Belgian biotechnology market had total revenues of $6.8 billion in 2011, representing a compound annual growth rate (CAGR) of 10.5% between 2007 and 2011. *The medical/healthcare segment was the market's most lucrative in 2011, with total revenue of $5.3 billion, equivalent to 77.5% of the market's overall value. Features Save time carrying out entry-level research by identifying the size, growth, and leading players in the biotechnology market in Belgium Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in Belgium Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance Add weight to presentations and pitches by understanding the future growth prospects of the Belgium biotechnology market with five year forecasts Macroeconomic indicators provide insight into general trends within the Belgium economy Key Questions Answered What was the size of the Belgium biotechnology market by value in 2011? What will be the size of the Belgium biotechnology market in 2016? What factors are affecting the strength of competition in the Belgium biotechnology market? How has the market performed over the last five years? Table of Contents : Executive Summary 2 Market value 2 Market value forecast 2 Category segmentation 2 Geography segmentation 2 Market rivalry 2 Market Overview 7 Market definition 7 Market analysis 7 Market Data 8 Market value 8 Market Segmentation 9 Category segmentation 9 Geography segmentation 10 Market Outlook 11 Market value forecast 11 Five Forces Analysis 12 Summary 12 Buyer power 13 Supplier power 14 New entrants 15 Threat of substitutes 16 Degree of rivalry 17 Leading Companies 18 AstraZeneca PLC 18 Novartis AG 22 Sanofi SA 25 ThromboGenics NV 28 Macroeconomic Indicators 29 Country Data 29 Appendix 31 Methodology 31 Industry associations 32 Related MarketLine research 32 LIST OF TABLES Table 1: Belgium biotechnology market value: $ billion, 2007–11 8 Table 2: Belgium biotechnology market category segmentation: $ billion, 2011 9 Table 3: Belgium biotechnology market geography segmentation: $ billion, 2011 10 Table 4: Belgium biotechnology market value forecast: $ billion, 2011–16 11 Table 5: AstraZeneca PLC: key facts 18 Table 6: AstraZeneca PLC: key financials ($) 19 Table 7: AstraZeneca PLC: key financial ratios 20 Table 8: Novartis AG: key facts 22 Table 9: Novartis AG: key financials ($) 23 Table 10: Novartis AG: key financial ratios 23 Table 11: Sanofi SA: key facts 25 Table 12: Sanofi SA: key financials ($) 26 Table 13: Sanofi SA: key financials (€) 26 Table 14: Sanofi SA: key financial ratios 26 Table 15: ThromboGenics NV: key facts 28 Table 16: Belgium size of population (million), 2007–11 29 Table 17: Belgium gdp (constant 2000 prices, $ billion), 2007–11 29 Table 18: Belgium gdp (current prices, $ billion), 2007–11 29 Table 19: Belgium inflation, 2007–11 30 Table 20: Belgium consumer price index (absolute), 2007–11 30 Table 21: Belgium exchange rate, 2007–11 30 LIST OF FIGURES Figure 1: Belgium biotechnology market value: $ billion, 2007–11 8 Figure 2: Belgium biotechnology market category segmentation: % share, by value, 2011 9 Figure 3: Belgium biotechnology market geography segmentation: % share, by value, 2011 10 Figure 4: Belgium biotechnology market value forecast: $ billion, 2011–16 11 Figure 5: Forces driving competition in the biotechnology market in Belgium, 2011 12 Figure 6: Drivers of buyer power in the biotechnology market in Belgium, 2011 13 Figure 7: Drivers of supplier power in the biotechnology market in Belgium, 2011 14 Figure 8: Factors influencing the likelihood of new entrants in the biotechnology market in Belgium, 2011 15 Figure 9: Factors influencing the threat of substitutes in the biotechnology market in Belgium, 2011 16 Figure 10: Drivers of degree of rivalry in the biotechnology market in Belgium, 2011 17 Figure 11: AstraZeneca PLC: revenues & profitability 20 Figure 12: AstraZeneca PLC: assets & liabilities 21 Figure 13: Novartis AG: revenues & profitability 23 Figure 14: Novartis AG: assets & liabilities 24 Figure 15: Sanofi SA: revenues & profitability 27 Figure 16: Sanofi SA: assets & liabilities 27